| Code | CSB-RA023986MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Denosumab-bmwo, targeting TNFSF11 (Tumor Necrosis Factor Superfamily Member 11), also known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). TNFSF11 is a critical cytokine that regulates osteoclast differentiation, activation, and survival, playing a central role in bone remodeling and calcium metabolism. By binding to its receptor RANK on osteoclast precursors, TNFSF11 promotes bone resorption, making it a key mediator in conditions characterized by excessive bone loss. Dysregulation of the RANKL/RANK pathway is implicated in osteoporosis, bone metastases, rheumatoid arthritis, and giant cell tumor of bone.
Denosumab-bmwo is a fully humanized IgG2 monoclonal antibody that neutralizes TNFSF11, preventing its interaction with RANK and thereby inhibiting osteoclast-mediated bone resorption. This biosimilar antibody serves as a valuable research tool for investigating bone metabolism, osteoclast biology, tumor-bone interactions, and the molecular mechanisms underlying skeletal disorders. It enables researchers to explore RANKL signaling pathways and evaluate potential therapeutic strategies targeting bone-related pathologies.
There are currently no reviews for this product.